Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Innate Pharma SA (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IPHA
Nasdaq
8731
https://www.innate-pharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Innate Pharma SA (ADR)
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
- Apr 15th, 2024 5:00 am
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- Apr 15th, 2024 5:00 am
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
- Apr 10th, 2024 4:00 pm
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
- Apr 10th, 2024 5:00 am
Innate Pharma Announces Its Participation in Upcoming Investor Conference
- Apr 9th, 2024 5:00 am
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
- Apr 5th, 2024 7:34 am
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript
- Mar 22nd, 2024 3:33 pm
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
- Mar 21st, 2024 6:00 am
Innate Pharma Announces Its Participation to Upcoming Investor Conference
- Mar 19th, 2024 6:00 am
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
- Mar 14th, 2024 6:00 am
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
- Mar 6th, 2024 6:00 am
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
- Mar 6th, 2024 6:00 am
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
- Jan 12th, 2024 6:00 am
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
- Jan 4th, 2024 5:40 pm
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
- Jan 4th, 2024 6:00 am
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
- Jan 4th, 2024 5:59 am
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
- Dec 19th, 2023 6:00 am
Innate Pharma Announces Leadership Change
- Dec 18th, 2023 6:00 am
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
- Dec 11th, 2023 6:00 am
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
- Dec 10th, 2023 6:00 am
Scroll